LINC-ROR and neoplasm: Furthermore, when administered during ex vivo expansion, ROR agonists increase the tumor-eliminating activity of cytotoxic Th17 cells and CAR-T cells, as well as the cytotoxic activity of human T cells, allowing tumors in tumor-bearing animals to be regressed.